Juveena Hydrogel System Feasibility Study for Heavy Menstrual Bleeding (HMB)

A Prospective Multicenter Safety and Feasibility Study of the Juveena Hydrogel System for Use for Temporary Control of Chronic Ovulatory Heavy Menstrual Bleeding (HMB)

This is a prospective, multicenter, single-arm interventional feasibility study to evaluate the safety and feasibility of the Juveena Hydrogel System for temporary control of heavy menstrual bleeding (HMB) in women with a history of chronic ovulatory HMB.

Study Overview

• Status: Recruiting
• Conditions: Heavy Menstrual Bleeding
• Intervention / Treatment: Device: Juveena Hydrogel System

Detailed Description

This is a prospective, multicenter, single-arm interventional feasibility study to evaluate the safety and feasibility of the Juveena Hydrogel System (HS) for temporary control of heavy menstrual bleeding (HMB) in women with a history of chronic ovulatory HMB.

Consenting subjects will be screened for eligibility and will have a baseline evaluation, including medical and gynecological history, and characterization of their menstrual cycle.

Eligible subjects will be tentatively scheduled for Juveena HS treatment, aiming for device placement no later than 3 days into the anticipated HMB component of their menstrual cycle. Subjects will be provided access to and instructions for populating a diary based on the Mansfield-Voda-Jorgensen (MVJ) menstrual bleeding scale, to be started on day 1 of the index menstrual period. On treatment day, eligibility will be confirmed (including confirmation of HMB and a negative urine pregnancy test) and an MVJ score documented pre- and post-treatment. Phone visits will be conducted post-treatment Days 1, 14 and 56. Clinic visits will be conducted post-treatment on Day 7 and Day 28.

• Study Type: Interventional
• Enrollment (Estimated): 7
• Phase: Not Applicable

Contacts and Locations

• Study Contact: Name: Ian Feldberg; Phone Number: 1-978-760-1742; Email: ian.feldberg@rejoni.com
• Study Contact Backup: Name: Jonathan Bissett; Phone Number: 1-617-877-7599; Email: jonathan.bissett@rejoni.com

Study Locations

• United States
  • Arizona
    • Phoenix, Arizona, United States, 85006
      • Withdrawn
      • Arizona Gynecology Consultants
  • Arkansas
    • Little Rock, Arkansas, United States, 72205
      • Recruiting
      • Applied Research Center of Arkansas
      • Contact: Olivia McIver; Phone Number: 870-917-8300; Email: olivia@arcarkansas.com
      • Principal Investigator: Nathan Livers, MD
  • New Jersey
    • West Orange, New Jersey, United States, 07052
      • Recruiting
      • Rubino OB/GYN (Axia Women's Health)
      • Principal Investigator: Robert Rubino, MD
      • Contact: Joanne Serra; Phone Number: 973-736-1100; Email: Joanne.Serra@axiawh.com
  • Ohio
    • Cincinnati, Ohio, United States, 45255
      • Completed
      • Seven Hills Clinical Research Group, LLC

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

1. Female aged 18 to 45 years inclusive seeking treatment for HMB
2. Recent history (within the last 3 months) of repeat periods of HMB that adversely affects quality of life (Modified SAMANTA score ≥4 and comprises at least three consecutive days of HMB, see Appendix 2).(23).
3. Historical menstrual pattern with at least 3 days (72 hours) of HMB as determined by retrospective MVJ Bleeding scale score of ≥5for prior cycle.
4. Menses frequency (24-38 days) based on subjectparticipant reporting.
5. Menses regularity - shortest to longest period is ≤8 days based on subjectparticipant reporting.
6. Actively experiencing heavy to very heavy menstrual bleeding (HMB) at the time of the Juveena HS treatment, i.e., MVJ score of ≥5 (treatment must be performed no later than Day 3 of the index period).
7. HMB refractory to hormone therapy, hormone therapy contraindicated, or subjectparticipant does not wish to continue hormone therapy.
8. The subjectparticipant is literate and clearly demonstrates an understanding of how to complete the MVJ Scale and other patient-reported outcomes.

9. Able and willing to comply with the study protocol and agrees to the following during participation in the study:

   1. Use an effective non-hormonal method of birth control until the Day 28 visit. Acceptable methods of birth control for use in this study are abstinence and barrier contraceptives (e.g. condom)
   2. No initiation or continuation of hormone use (including contraception) or any other medical intervention for bleeding until after the Day 28 visit (unless clinically necessary, e.g., the subjectparticipant becomes hemodynamically unstable)
   3. Attends the follow-up examexams and completion of electronic diaries via a secured internet website (subject must have internet accesscompletes the MVJ scale and will be trained on how to use the eDiary)other patient-reported outcomes per the schedule of events
10. Demonstrates understanding of the study and signs the written informed consent form.

Exclusion Criteria:

1. Pregnancy and/or breastfeeding within the past 3 months or planning to become pregnant during the duration of this study.
2. Currently using an intrauterine device (IUD) or has undergone removal within the last 2 menstrual cycles.
3. Dysmenorrhea of a severity that, in the opinion of the investigator, precludes participation in the study.
4. Hemoglobin of < 8 g/dL at the time of screening.
5. Suspected or known malignancy or premalignant condition of the uterus including the cervix
6. Active pelvic infection.
7. Active sexually transmitted disease (STD) at the time of treatment (STD testing to be performed)
8. Presence of bacteremia, sepsis, or other active systemic infection
9. Currently on anticoagulants
10. History of allergies to PEG or FD&C Blue#1 dye
11. Planning to undergo surgery or other treatments for HMB during the study period (i.e., 8 weeks post-hydrogel instillation).
12. AUB-L sm with a Type 0 or 1 leiomyoma > 1 cm
13. AUB-P (Polyp) > 2 cm in maximum dimension based on ultrasound, hysteroscopy, or MRI performed within prior 6 months.
14. AUB-O, Irregular menstrual cycles (cycle length variability >7 days length)
15. AUB-C (coagulopathy or bleeding disorder)
16. Any patient who is currently participating or considering participation in any other research of an investigational drug or device. Does not include observational studies
17. Any general health, mental health, or social situation which, in the opinion of the investigator, could represent an increased risk for the patient or the ability of the patient to complete study requirements.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Device Feasibility
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Juveena Hydrogel System; One time instillation of the Juveena Hydrogel into the uterine cavity.	Device: Juveena Hydrogel System; The Juveena Hydrogel System is a single-use device that is instilled into the endometrial cavity as a liquid and sets up as a gel intrauterine tamponade within seconds.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Primary Effectiveness Endpoint	Feasibility for invoking a tamponade effect	Within 7 days post-treatment

Other Outcome Measures

Outcome Measure	Measure Description	Time Frame
Bleeding Control	The proportion of subjects achieving bleeding control defined as none or spotting (MVJ ≤1)	Within 7 days post-treatment

Collaborators and Investigators

• Sponsor: Rejoni Inc.

Study record dates

Study Major Dates

• Study Start (Actual): February 1, 2025
• Primary Completion (Estimated): June 30, 2026
• Study Completion (Estimated): June 30, 2026

Study Registration Dates

• First Submitted: October 7, 2024
• First Submitted That Met QC Criteria: October 8, 2024
• First Posted (Actual): October 10, 2024

Study Record Updates

• Last Update Posted (Actual): April 27, 2026
• Last Update Submitted That Met QC Criteria: April 22, 2026
• Last Verified: April 1, 2026

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Urogenital Diseases; Genital Diseases; Pathologic Processes; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Uterine Diseases; Genital Diseases, Female; Hemorrhage; Uterine Hemorrhage; Menstruation Disturbances; Pathological Conditions, Signs and Symptoms; Menorrhagia
• Other Study ID Numbers: REJ-CT-0008

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: Yes
• product manufactured in and exported from the U.S.: No